Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0596263 (
carcinogenesis
)
64,820
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background
. Globally, approximately 20% of malignancy are caused by infection. Schistosoma infection is a major cause of bladder in most part of Africa. In 2018 alone, there were approximately 549,393 new cases and 199,922 deaths from bladder cancer. The presence of Schistosoma ova in the venous plexus of the bladder induces a cascade of inflammation causing significant tissue damage and granulomatous changes.
Methodology
. A literature review was conducted from 1995 to 2019 using PubMed, Google Scholar, African Journal Online, and Google databases. Relevant data on the association of "Schistosomiasis and
Bladder
cancer" in sub-Saharan Africa (SSA) were retrieved.
Evidence Synthesis
. Results from research using animal models to establish the
carcinogenesis
of Schistosoma and bladder cancer have been helpful but inconclusive. Immunoregulatory cytokines and genetic marker have been identified to play a role in the pathogenesis. In some parts of sub-Saharan Africa, there has been close association of squamous cell carcinoma and histological evidence of Schistosoma ova.
Conclusion
. There are some data to support the association between schistosomiasis and bladder cancer in sub-Saharan Africa. However, these have been limited by their design and may not sufficiently establish
carcinogenesis
. There is a need for more genomic and molecular research to better characterize
S. haematobium
and its effects on the bladder. Such goal will contribute immensely to Schistosoma bladder cancer prevention and control.
...
PMID:Is Schistosomiasis a Risk Factor for Bladder Cancer? Evidence-Based Facts. 3256 32
Despite aggressive treatment approaches, muscle-invasive bladder urothelial carcinoma (MIBC) patients still have a 50% chance of developing general incurable metastases. Therefore, there is an urgent need for candidate markers to enhance diagnosis and generate effective treatments for this disease. We evaluated four mRNA microarray datasets to find differences between non-MIBC (NMIBC) and MIBC tissues. Through a gene expression profile analysis via the Gene Expression Omnibus database, we identified 56 differentially expressed genes (DEGs). Enrichment analysis of gene ontology, Kyoto Encyclopedia of Genes and Genomes, and Reactome pathways revealed the interactions between these DEGs. Next, we established a protein-protein interaction network to determine the interrelationship between the DEGs and selected 10 hub genes accordingly.
Bladder
urothelial carcinoma (BLCA) patients with
COL1A2
,
COL5A1
, and
COL5A2
alterations showed poor disease-free survival rates, while BLCA patients with
COL1A1
and
LUM
alterations showed poor overall survival rates. Oncomine analysis of MIBC versus NMIBC tissues showed that
COL1A1
,
COL5A2
,
COL1A2
, and
COL3A1
were consistently among the top 20 overexpressed genes in different studies. Using the TCGAportal, we noted that the high expression of each of the four genes led to shorter BLCA patient overall survival. It was evident that BLCA patients with an elevated high combined gene expression had significantly shorter overall survival and relapse-free survival than those with low combined gene expression using PROGgeneV2. Using Gene Expression Profiling Interactive Analysis, we noted that
COL1A1
,
COL1A2
,
COL3A1
, and
COL5A2
were positively correlated with each other in BLCA. These genes are considered as clinically relevant genes, suggesting that they may play an important role in the
carcinogenesis
, development, invasion, and metastasis of MIBC. However, considering we adopted a bioinformatic approach, more research is crucial to confirm our results. Nonetheless, our findings may have important prospective clinical implementations.
...
PMID:Bioinformatic Identification of Potential Hub Genes in Muscle-Invasive Bladder Urothelial Carcinoma. 3303 17
<< Previous
1
2
3
4
5